Influence of spacer device on drug delivery to young children with asthma.

L Agertoft, S Pedersen

Department of Paediatrics, Kolding Hospital, Denmark.

The budesonide dose delivered to the patient from three different spacer devices (Nebuhaler = 750 ml, Aerochamber = 140 ml, and Babyspacer = 260 ml) was assessed by measuring the budesonide dose deposited on a filter inserted between the spacer outlet and the mouth of the patient. Twenty children aged 10-25 months were given a single dose of 200 micrograms budesonide from each spacer device in a randomised crossover study. All spacers had a facemask attached and a one way valve system. The children breathed through the inhalation system for 30 seconds. Furthermore, the minute ventilation of the children through a tightly fitting facemask was measured. The filter dose of budesonide was significantly lower after Aerochamber treatment (39.4 micrograms, range 19-67 micrograms) than after Nebuhaler (53.5 micrograms, range 34-88 micrograms) and Babyspacer (55.5 micrograms, range 39-76 micrograms) treatment. The minute ventilation of the children varied from 1.4 l/min to 7.0 l/min (mean 5.0 l/min). This was sufficient to empty all spacers within the 30 seconds of inhalation. It is concluded that spacer volume does not seem to be so important for children aged 10-25 months as long as spacers with a volume lower than 750 ml are used.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Commentary

Michael Silverman
Arch. Dis. Child. 1994 71: 219-220. [PDF]

This article has been cited by other articles:

• Wright, J, Brocklebank, D, Ram, F (2002). Inhaler devices for the treatment of asthma and chronic obstructive airways disease (COPD). Qual Saf Health Care 11: 376-382 [Abstract] [Full Text]  
• Amirav, I., Newhouse, M. T. (2001). Aerosol Therapy With Valved Holding Chambers in Young Children: Importance of the Facemask Seal. Pediatrics 108: 389-394 [Abstract] [Full Text]  
• Adams, R. J., Fuhlbrigge, A., Finkelstein, J. A., Lozano, P., Livingston, J. M., Weiss, K. B., Weiss, S. T. (2001). Use of Inhaled Anti-inflammatory Medication in Children With Asthma in Managed Care Settings. Arch Pediatr Adolesc Med 155: 501-507 [Abstract] [Full Text]  
• MELLON, M., LEFLEIN, J., WALTON-BOWEN, K., CRUZ-RIVERA, M., FITZPATRICK, S., SMITH, J. A. (2000). Comparable Efficacy of Administration with Face Mask or Mouthpiece of Nebulized Budesonide Inhalation Suspension for Infants and Young Children with Persistent Asthma. Am. J. Respir. Crit. Care Med. 162: 593-598 [Abstract] [Full Text]  
• O'CALLAGHAN, C., BARRY, P. W (2000). How to choose delivery devices for asthma. Arch. Dis. Child. 82: 185-187 [Full Text]  
• (2000). Inhaler devices for asthma. DTB 38: 9-14 [Abstract] [Full Text]  
• Agertoft, L, Andersen, A, Weibull, E, Pedersen, S (1999). Systemic availability and pharmacokinetics of nebulised budesonide in preschool children. Arch. Dis. Child. 80: 241-247 [Abstract] [Full Text]